[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100483652":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":23,"centralContacts":27,"locations":38,"responsibleParty":57,"collaborators":60,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":72,"sex":78,"minAge":79,"maxAge":32,"enrollmentInfo":80,"targetDuration":32,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":92,"overallStatus":40,"whyStopped":32,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Massachusetts General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients 65 and older with Heart Failure with Preserved Ejection Fraction","EXPERIMENTAL","Patients 65 years and older presenting to Massachusetts General Hospital with a known diagnosis of HFpEF and without a diagnosis of amyloidosis in the ambulatory (outpatient) setting will undergo a 99Tc-Pyrophosphate Scan to identify Cardiac Amyloidosis",[13],"Diagnostic Test: 99mTc-pyrophosphate Scintigraphy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","99mTc-pyrophosphate Scintigraphy","Cardiac Imaging Technique used to diagnose Transthyretin Cardiac Amyloidosis by use of 15 mCi of 99mTC-Pyrophosphate tracer",[9],[21,22],"PYP Scan","Pyrophosphate Scan",[24],{"name":25,"affiliation":5,"role":26},"Hanna K Gaggin, MD","PRINCIPAL_INVESTIGATOR",[28,34],{"name":29,"role":30,"phone":31,"phoneExt":32,"email":33},"Abbie Macher, BS","CONTACT","617-643-6328",null,"ajmacher@mgh.harvard.edu",{"name":35,"role":30,"phone":36,"phoneExt":32,"email":37},"Laura Stockhausen, BS","617-724-1339","lstockhausen@mgh.harvard.edu",[39],{"facility":5,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"RECRUITING","Boston","Massachusetts","02114","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-71.05977,42.35843,{"lat":50,"lon":49},[53,55],{"name":54,"role":30,"phone":32,"phoneExt":32,"email":32},"Heather Jameson, PhD",{"name":56,"role":26,"phone":32,"phoneExt":32,"email":32},"Hanna Gaggin, MD",{"type":26,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"Hanna Kim Gaggin","Principal Investigator, Associate Professor of Medicine",[61,64,66,68],{"name":62,"class":63},"Akcea Therapeutics","INDUSTRY",{"name":65,"class":63},"Pfizer",{"name":67,"class":63},"Alnylam Pharmaceuticals",{"name":69,"class":63},"Eidos Therapeutics, a BridgeBio company","100483652","prevalence-and-prediction-of-attr-in-ambulatory-patients-with-hfpef-100483652",false,"NCT05577819","Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF","Prevalence and Prediction of Transthyretin Amyloidosis in Ambulatory Patients With Heart Failure With Preserved Ejection Fraction","TTRinHFpEF","Inclusion Criteria:\n\n* Patients with a confirmed diagnosis of HFpEF.\n* Age ≥65 years old\n\nExclusion Criteria:\n\n* End stage chronic kidney disease on dialysis (CKD stage 5 as defined as eGFR \\\u003C15mL\u002Fmin)\n* no history of HFrEF (LVEF\\\u003C40%) with the exception of low LVEF in the setting of acute decompensation, AF RVR, ACS\u002FMI, etc\n* Negative 99mTc-pyrophosphate scan within a year\n* Unable to lie down for 15 minutes for the 99mTc-pyrophosphate scan\n* Known diagnosis of amyloidosis\n* Severe valvular heart disease that is uncorrected (moderate to severe is considered exclusionary)","ALL","65 Years",{"count":81,"type":82},515,"ESTIMATED","INTERVENTIONAL",[85],"NA","Recent studies have shown that transthyretin amyloidosis (ATTR) can sometimes cause a type of heart failure where the pumping function of the heart is normal, also known as Heart Failure with Preserved Ejection Fraction (HFpEF) or diastolic heart failure. In this single center diagnostic study, we will evaluate for ATTR in patients with HFpEF in order to to determine how frequently this occurs and how we can predict which heart failure patients may have TTR amyloidosis. Our goal is to identify amyloidosis in heart failure patients earlier so that they can start treatment.",[88,89,90,91],"Transthyretin Amyloidosis","Heart Failure","Heart Failure, Diastolic","Amyloidosis",[88,89,90,91],"2024-12-06",{"date":95,"type":96},"2024-12-09","ACTUAL",{"date":98,"type":96},"2020-10-02",{"date":100,"type":82},"2026-12-31",{"name":5,"class":6},1]